RU2014144700A - Methods for influencing UBE3A gene expression - Google Patents

Methods for influencing UBE3A gene expression Download PDF

Info

Publication number
RU2014144700A
RU2014144700A RU2014144700A RU2014144700A RU2014144700A RU 2014144700 A RU2014144700 A RU 2014144700A RU 2014144700 A RU2014144700 A RU 2014144700A RU 2014144700 A RU2014144700 A RU 2014144700A RU 2014144700 A RU2014144700 A RU 2014144700A
Authority
RU
Russia
Prior art keywords
sequence
gene
ube3a
influencing
ube3a gene
Prior art date
Application number
RU2014144700A
Other languages
Russian (ru)
Inventor
Алла Дмитриевна Газзаева
Original Assignee
Алла Дмитриевна Газзаева
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алла Дмитриевна Газзаева filed Critical Алла Дмитриевна Газзаева
Priority to RU2014144700A priority Critical patent/RU2014144700A/en
Publication of RU2014144700A publication Critical patent/RU2014144700A/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1. Способ воздействия на экспрессию гена UBE3A в клетках пациента, включающий приведение в контакт указанных клеток с одним или несколькими антисмысловыми олигонуклеотидами, где последовательность, по меньшей мере, на 70% идентична последовательности указанного гена.2. Способ по п.1, где экспрессию повышают.3. Синтетический олигонуклеотид, имеющий последовательность, на 70% идентичную последовательности гена UBE3A.4. Синтетический олигонуклеотид по п.3, где олигонуклеотид имеет последовательность, на 80% идентичную последовательности гена UBE3A.5. Композиция, содержащая один или более синтетических олигонуклеотидов по п.3.6. Способ лечения заболевания, связанного с геном UBE3A, включающий введение пациенту эффективной дозы одного ли нескольких олигонуклеотидов по п.3.1. A method of influencing the expression of a UBE3A gene in a patient’s cells, comprising contacting said cells with one or more antisense oligonucleotides, wherein the sequence is at least 70% identical to the sequence of the indicated gene. The method of claim 1, wherein the expression is enhanced. A synthetic oligonucleotide having a sequence 70% identical to the sequence of the UBE3A.4 gene. The synthetic oligonucleotide according to claim 3, wherein the oligonucleotide has a sequence that is 80% identical to the sequence of the UBE3A.5 gene. A composition comprising one or more synthetic oligonucleotides according to claim 3.6. A method of treating a disease associated with the UBE3A gene, comprising administering to the patient an effective dose of one or more oligonucleotides according to claim 3.

Claims (6)

1. Способ воздействия на экспрессию гена UBE3A в клетках пациента, включающий приведение в контакт указанных клеток с одним или несколькими антисмысловыми олигонуклеотидами, где последовательность, по меньшей мере, на 70% идентична последовательности указанного гена.1. A method of influencing the expression of a UBE3A gene in a patient’s cells, comprising contacting said cells with one or more antisense oligonucleotides, wherein the sequence is at least 70% identical to the sequence of the indicated gene. 2. Способ по п.1, где экспрессию повышают.2. The method according to claim 1, where the expression is increased. 3. Синтетический олигонуклеотид, имеющий последовательность, на 70% идентичную последовательности гена UBE3A.3. A synthetic oligonucleotide having a sequence 70% identical to the sequence of the UBE3A gene. 4. Синтетический олигонуклеотид по п.3, где олигонуклеотид имеет последовательность, на 80% идентичную последовательности гена UBE3A.4. The synthetic oligonucleotide according to claim 3, where the oligonucleotide has a sequence that is 80% identical to the sequence of the UBE3A gene. 5. Композиция, содержащая один или более синтетических олигонуклеотидов по п.3.5. A composition comprising one or more synthetic oligonucleotides according to claim 3. 6. Способ лечения заболевания, связанного с геном UBE3A, включающий введение пациенту эффективной дозы одного ли нескольких олигонуклеотидов по п.3. 6. A method of treating a disease associated with the UBE3A gene, comprising administering to the patient an effective dose of one or more oligonucleotides according to claim 3.
RU2014144700A 2014-11-07 2014-11-07 Methods for influencing UBE3A gene expression RU2014144700A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2014144700A RU2014144700A (en) 2014-11-07 2014-11-07 Methods for influencing UBE3A gene expression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2014144700A RU2014144700A (en) 2014-11-07 2014-11-07 Methods for influencing UBE3A gene expression

Publications (1)

Publication Number Publication Date
RU2014144700A true RU2014144700A (en) 2016-06-10

Family

ID=56114696

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014144700A RU2014144700A (en) 2014-11-07 2014-11-07 Methods for influencing UBE3A gene expression

Country Status (1)

Country Link
RU (1) RU2014144700A (en)

Similar Documents

Publication Publication Date Title
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
BR112016022742A2 (en) compositions and methods for modulating growth hormone receptor expression
BR112017004349A2 (en) globin gene therapy for treatment of hemoglobinopathies
AR101312A1 (en) COMBINATIONS OF BET INHIBITORS AND INHIBITORS OF TIROSINA QUINASA DE BRUTON
BR112015023439A2 (en) combination of cancer treatments using micro-ovens and egfr-tki inhibitors
TR201818825T4 (en) LNCRNAS FOR THE TREATMENT AND DIAGNOSIS OF CARDIAC HYPERTROPHY
BR112018003526A2 (en) methods of treating inflammatory diseases
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
EA201791471A1 (en) METHODS OF APPLICATION OF ANTI-SMART OLIGONUCLEOTIDE SMAD7
BR112019005040A2 (en) pridopidine application for rett syndrome treatment
MX2015012444A (en) Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens.
BR112018008931A8 (en) "compounds for treating hypoproliferative disorders"
UY35328A (en) TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
CY1122708T1 (en) OXA-DIAZASPIRE COMPOUNDS WITH ACTION AGAINST PAIN
BR112018010736A2 (en) antisense oligonucleotides against il-34 and methods of using them
MY194135A (en) Treatment and diagnosis of inflammatory disorders
RU2014144700A (en) Methods for influencing UBE3A gene expression
RU2014146616A (en) Methods for influencing SNRPN gene expression
RU2014142752A (en) Methods for influencing lactase gene expression
RU2014142756A (en) Methods for influencing D4DR gene expression
RU2014142755A (en) Methods for influencing CYP17 gene expression
RU2014141738A (en) Methods for influencing CFTR gene expression
BR112017011513A2 (en) treatment of eye conditions using progenitor cells
RU2014144094A (en) Methods for influencing CREBBP gene expression